ClinicalTrials.gg
CompletedNCT01000922Updated Jul 29, 2015

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

A Phase 2 interventional study of Regular Human Insulin and Lispro in Diabetes Mellitus, sponsored by Biodel. Completed at 1 site in United States. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-07-29.

Sponsored by Biodel · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus.

Enrollment
31st of 41
24 · median 60
Started
2006
with 5 others
Phase 2
3 of 41
1 open now
Registered
25th of 41
by date
Lead sponsor
4 of 41
Biodel

Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, this one is the 31st largest by enrollment, is one of 6 that started in 2006, is one of 3 in phase 2, and was the 25th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, or all of them as a file.
02

Study summary

Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • Mealtime Insulin
  • Rapid acting insulin
  • Ultra fast VIAject
  • prandial insulin
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Established diagnosis of type 1 diabetes for not less than 5 years
  2. values of not more than 9%
  3. Age: 19 to 70 years
  4. Sex: Male or Female
  5. : 18 - 28 kg/m2
  6. must be obtained in writing for all volunteers.

Exclusion criteria

Exclusion Criteria:

  1. Type 2 Diabetes mellitus.
  2. History of to any of the components in the study medication.
  3. History of severe or multiple allergies.
  4. Treatment with any other drug in the last 1 month before study entry.
  5. Treatment with any concomitant medication that in the judgment of the investigator. would interfere with the study results.
  6. Progressive disease likely to prove fatal (e.g. ).
  7. Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair subject safety or protocol compliance.
  8. Having a significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the investigator.
  9. Blood donation within the last 30 days.
  10. A women who is lactating.
  11. Pregnant women or women intending to become pregnant during the study.
  12. A sexually active woman of childbearing age not actively practicing by using a medically accepted device or therapy.
  13. Positive Serology for , or .
  14. Abnormal , safety lab or physical examination results that are deemed by the investigator.
  15. A lack of compliance or other reasons which, in the opinion of the investigator, prevent the participation of the subject in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Regular Human Insulin

    Single injection

    Drug: Regular Human Insulin

  • Experimental
    Lispro

    Single injection

    Drug: Lispro

  • Experimental
    VIAject

    Single injection

    Drug: VIAject

  • Experimental
    VIAject 50%

    Single injection

    Drug: VIAject 50%

  • Experimental
    VIAject/Insulin glargine

    Single injection

    Drug: VIAject/Insulin Glargine

  • Experimental
    Insulin Glargine/VIAject

    Single injection

    Drug: Insulin Glargine/VIAject

Interventions

  • Individual dose of RHI administered subcutaneously

  • DrugLispro

    Individual dose of lispro administered subcutaneously

  • Individual dose of VIAject administered subcutaneously

  • DrugVIAject 50%

    Individual dose of VIAject 50% administered subcutaneously

  • DrugVIAject/Insulin Glargine

    VIAject mixed wiht insulin glargine and administered subcutaneously

  • DrugInsulin Glargine/VIAject

    Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously

06

What researchers measure

Primary outcomes

  1. To compare the maximal post prandial blood glucose concentration and the time to maximal post prandial glucose concentration between the different treatments

    Time frame: 8 hours

Secondary outcomes

  1. To compare the ppGlucmax for all treatments, the ppTGluc-max, the AUCGluc 0-180 and the AUCGluc 0-360, CGluc-baseline for all treatments.

    Time frame: 8 hours

07

Study locations

1 site
  • Profil Institute for Clinical Research, Inc. (PICR)
    Chula Vista, California 91911, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2009
First posted
Oct 23, 2009
Start
Jun 2006
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results delay requested
Jul 28, 2015
Last update
Jul 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01000922
Lead sponsor
Biodel
Responsible party
Sponsor
First posted
Oct 23, 2009
Start date
Jun 2006
Primary completion
Jan 2008
Completion
Jan 2008
Last update
Jul 29, 2015

Study contacts

Marcus Hompesch, MD
principal investigator · Profil Institute for Clinical Research, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin, Regular, Human · Insulin Lispro

Start the discussion